Publicacións en colaboración con investigadores/as de University of Edinburgh (36)

2024

  1. Airway and Blood Monocyte Transcriptomic Profiling Reveals an Antiviral Phenotype in Infants With Severe Respiratory Syncytial Virus Infection

    Journal of Infectious Diseases, Vol. 229, pp. S100-S111

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Adeno-associated virus 2 infection in children with non-A–E hepatitis

    Nature, Vol. 617, Núm. 7961, pp. 555-563

  3. Genomic investigations of unexplained acute hepatitis in children

    Nature, Vol. 617, Núm. 7961, pp. 564-573

2022

  1. A Systematic Review and Meta-analysis of Animal Studies Investigating the Relationship Between Serum Antibody, T Lymphocytes, and Respiratory Syncytial Virus Disease

    The Journal of infectious diseases, Vol. 226, Núm. 1, pp. S117-S129

  2. Age-Specific Estimates of Respiratory Syncytial Virus-Associated Hospitalizations in 6 European Countries: A Time Series Analysis

    Journal of Infectious Diseases, Vol. 226, pp. S29-S37

  3. Global Disease Burden of Respiratory Syncytial Virus in Preterm Children in 2019: A Systematic Review and Individual Participant Data Meta-Analysis Protocol

    Journal of Infectious Diseases, Vol. 226, pp. S135-S141

  4. Mapping genomic loci implicates genes and synaptic biology in schizophrenia

    Nature, Vol. 604, Núm. 7906, pp. 502-508

  5. Patient Involvement in RSV Research: Towards Patients Setting the Research Agenda

    Journal of Infectious Diseases, Vol. 226, pp. S130-S134

  6. Year-to-year variation in attack rates could result in underpowered respiratory syncytial virus vaccine efficacy trials

    Journal of Clinical Epidemiology, Vol. 147, pp. 11-20

2021

  1. Immunological and inflammatory biomarkers of susceptibility and severity in adult respiratory syncytial virus infections

    Journal of Infectious Diseases, Vol. 222, pp. S584-S591

  2. Nebulised ALX-0171 for respiratory syncytial virus lower respiratory tract infection in hospitalised children: a double-blind, randomised, placebo-controlled, phase 2b trial

    The Lancet Respiratory Medicine, Vol. 9, Núm. 1, pp. 21-32

2020

  1. Low Sensitivity of BinaxNOW RSV in Infants

    The Journal of infectious diseases, Vol. 222, Núm. 7, pp. S640-S647

  2. Respiratory Syncytial Virus Consortium in Europe (RESCEU) Birth Cohort Study: Defining the Burden of Infant Respiratory Syncytial Virus Disease in Europe

    The Journal of infectious diseases, Vol. 222, Núm. 7, pp. S606-S612

2019

  1. Analysis of Outcomes in Ischemic vs Nonischemic Cardiomyopathy in Patients with Atrial Fibrillation: A Report from the GARFIELD-AF Registry

    JAMA Cardiology, Vol. 4, Núm. 6, pp. 526-548

  2. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

    The Lancet Diabetes and Endocrinology, Vol. 7, Núm. 8, pp. 618-628

  3. Lung Cancer Risk in Never-Smokers of European Descent is Associated With Genetic Variation in the 5p15.33 TERT-CLPTM1Ll Region

    Journal of Thoracic Oncology, Vol. 14, Núm. 8, pp. 1360-1369

2018

  1. Respiratory syncytial virus seasonality: A global overview

    Journal of Infectious Diseases, Vol. 217, Núm. 9, pp. 1356-1364

  2. Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: Rationale for comprehensive management of atrial fibrillation

    PLoS ONE, Vol. 13, Núm. 1

2017

  1. Improved risk stratification of patients with atrial fibrillation: An integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation

    BMJ Open, Vol. 7, Núm. 12